David Bearss Resigns as Chief Scientific Officer to Join Huntsman Cancer Institute as Co-director of Center for Investigational Therapeutics
Published: Sep 21, 2009
DUBLIN, Calif.--(BUSINESS WIRE)--SuperGen Inc. (Nasdaq:SUPG) announced that, effective October 16, 2009, David Bearss, Ph.D., will resign as SuperGen’s Chief Scientific Officer, and be engaged as a long-term biology consultant to the Company. In addition, Dr. Bearss will retain his Scientific Advisory Board membership at SuperGen. Dr. Bearss will return to academic cancer research, as Co-director of the Center for Investigational Therapeutics of Huntsman Cancer Institute at the University of Utah.